Zoetis Q2 2024: revenue $2.4B (+11% op), adj EPS $1.56 (+20% op), raises FY guidance

Zoetis Inc.

2024-Q2 EPS reported $2.67 revenue$4,551,000,000

Revenue $2.4B, +8% reported / +11% operational; U.S. +12%, International +10% op.
GAAP net income $624M (-7%), diluted EPS $1.37 (-6%).
Adjusted net income $711M (+9% reported, +18% operational), adjusted diluted EPS $1.56 (+11% reported, +20% operational).
FY2024 guidance raised: revenue $9.100-9.250B, adj EPS $5.78-5.88; op rev growth 9-11%, op adj NI growth 13.5-15.5%.
Growth led by mAb OA pain products Librela/Solensia, Simparica Trio, and dermatology portfolio Apoquel/Cytopoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.